HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) could be one of the worst stocks that investors may not want to consider for their portfolio today as the company shares are trading 2.6% or 0.021 points down from last closing price of $0.801, reaching $0.7802 at last check. Any clue why there is so much of action in the HTGM stock? The share price has dropped in 3 of the last 5 days and is down -62.77% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -8,321 shares, and in total 286579 shares valued at $223589 were seen changing hands compared with 294900 shares valued at $236215 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the HTGM stock is near its bottom.
HTG Molecular Diagnostics, Inc. (HTGM) shares have notched a 3-month decline of about -62.77%, but has still tumbled -68.48% year to date. By comparison, the stock sank -81.6% over the past 12 months, while it slipped -24.48% over the 1 month. The company’s market cap is around $22.09M, with its short interest ratio standing at 13.03%.
In the current trading session for HTGM, the stock witnessed two major price actions, it rose to a high of $0.8199 and was down as much as $0.7498 at one point. The high recorded is very low when compared to their 52-week high which is $0.79. The 52-week high is now at -85.53 distance from current price. Their recent low of $5.46 represents a -0.01% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for HTGM is $4.8, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of HTG Molecular Diagnostics, Inc. earned $-0.6 per share in the trailing 12 months and has a P/E ratio of -1.3. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 30.46 and lower compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. HTGM also has P/S multiple of 1.01. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.34x.
HTGM‘s last price was down -63.08% as compared to the average trading price of 50 days recorded at $2.11 while enlarging the period to 200 trading days, the average closing price was $1.18. At present, there are 27.6 million in the total number of common shares owned by the public and among those 24.87 million shares have been available to trade. The percentage of shares being held by the company management was 2.2% while institutions stake was 45.8%. The company has generated negative returns on equity over the last 12 months (-95.8%). It managed to keep its gross profit margin at 67.1% over the past 12 months.
When assessing the full upside of the HTGM stock, there is another set of technicals that should be looked into and considered. Its -13.28% decline from moving average of $0.9 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.62 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of HTG Molecular Diagnostics, Inc. — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $5.25 on shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), which corresponds to 581.82% upside potential than its current market price of $0.7802 and implies potential despite the recent drop in the price. However, their current target price has fallen from $5.25 a month ago and is down handily from the consensus target of $6.75 a quarter ago.
In the last five years, the EPS of the company has been roughly 22.3%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 57.2 over the last five years. The company recently recorded an increase of 18.4%, but this figure is rather attractive.
Let’s briefly check the hedge fund interest towards HTGM stock. Price T Rowe Associates Inc. MD trimmed position in the company after it dumped -0.5% or 2,002,714 shares of its common stock. The hedge fund now owns 1,992,700 shares worth $1,554,705, SEC documents show. Citadel Advisors LLC shored up assets in the stock as 15173.3 shares have been purchased, increasing its stake by 153.9% to 38,525 shares which are currently valued at $30,057. In addition, Vanguard Group Inc. recently reported that it now owns 1,453,160 shares making a total of $1,133,755 based on the recent price. This refelects a change of 20% in their ownership.